Patient-specific neoantigen–human leukocyte antigen complexes (NeoAg-HLA complexes)

Patient-specific neoantigen–HLA complexes are unique molecular assemblies formed when mutated proteins derived from somatic tumor mutations are processed into short peptides and presented on the cell surface by Human Leukocyte Antigen (HLA) molecules. These complexes are highly specific to the individual's tumor and are absent in healthy tissues, making them ideal targets for precision immunotherapy as they bypass central thymic tolerance. In the context of oncology, these complexes serve as the primary recognition signal for the adaptive immune system, specifically for CD8+ cytotoxic T cells and CD4+ helper T cells. Therapeutic interventions such as personalized mRNA vaccines, peptide vaccines, and engineered T-cell receptor (TCR) therapies are designed to prime or direct the immune system to recognize these specific peptide-HLA combinations. The identification of these targets requires advanced genomic sequencing and bioinformatic algorithms to predict which mutations will result in stable, immunogenic complexes on the patient's specific HLA alleles. Consequently, they represent a cornerstone of personalized cancer medicine, aiming to induce a potent, durable, and highly selective anti-tumor immune response while minimizing off-target toxicity.

Other names

Tumor-specific neoantigen-MHC complexesNeoepitope-HLA complexesPersonalized neoantigensMutant peptide-MHC complexespMHC complexesTumor-specific antigens (TSAs)

Induction of tumor-specific T-cell responses (CD8+ and CD4+) by presenting non-self mutant peptides to the immune system, leading to targeted lysis of tumor cells.